Shots:
- Hanmi Pharm has granted Eli Lilly exclusive global rights (excl. Korea) to develop, manufacture & commercialize sonefpeglutide, a GLP-2 analog incorporating Hanmi’s long-acting platform tech, Lapscovery
- As per the deal, Hanmi will receive $75M upfront & up to $1.185B in clinical development, regulatory approval, and commercialization milestone payments, with royalties following product launch
- Hanmi will continue to lead & complete the ongoing global P-II trial of sonefpeglutide in short bowel syndrome, while Lilly will evaluate additional development opportunities & potential future clinical studies based on the therapy’s preclinical & clinical data
Ref: Prnewswire | Image: Hanmi Pharm & Eli Lilly | Press Release
Related News: Eli Lilly Builds Infectious Disease Pipeline With 3 Acquisitions Valued ~$3.8B
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
